Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
Sexual harassment in pharmacy
It took Bria Lacy five years to ‘find her voice’ but when she did, it was heard.
I was not expecting the overwhelming response I...
Coping with COVID-19: the Royal Melbourne Hospital experience
COVID-19 has fostered an even closer relationship between the pharmacy and wards of the Royal Melbourne Hospital.
Breaking the seal
These are the four areas pharmacists need to consider when manipulating or repackaging commercial products.
Australians line up at pharmacies for winter dose
On 11 July, 7.4 million Australians became eligible for a COVID-19 winter dose after the eligibility criteria widened.
The best apps for sleep
A range of devices and apps are tailored to monitor and promote restful sleep. Here’s the pick of the field.
Just over a third (39%)...
Have your voice heard with PSA’s Communities of Specialty Interest
Pharmacists across the country have a new way to connect, collaborate and drive the profession forward, with the launch of PSA’s Communities of Specialty Interest (CSIs).
